Cross-Sector entity
Every one of those 2 sits in a single category, regulation. Of the tracked stories, 2 of 2 also mention Controlled Substances Act, the most common co-covered peer. Each carries 4 original sources on average. We currently track 2 Cross-Sector stories that mention Catalent, all published on July 30, 2026.
2 verified stories tracked
Last mentioned: Jul 30, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, regulation. Of the tracked stories, 2 of 2 also mention Controlled Substances Act, the most common co-covered peer. Each carries 4 original sources on average. We currently track 2 Cross-Sector stories that mention Catalent, all published on July 30, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Catalent. Shared-story counts are live from our verified record — not editorial picks.
Attorney General orders marijuana moved to Schedule III
The AG issues an order rescheduling state‑licensed medical marijuana and establishing a novel federal registration system for state marijuana businesses.
MMJ files DEA bulk‑manufacturer application
MMJ International Holdings submits an application to manufacture active pharmaceutical ingredients for cannabinoid drugs, which remains pending nearly eight years later.
A D.C. Circuit review of the Attorney General’s April 2026 order moving medical marijuana to Schedule III puts administrative law front and center. MMJ International Holdings argues the AG skipped required rulemaking and evidentiary hearings, threatening the integrity of the Controlled Substances Act’s scheduling process.
Investors face renewed uncertainty as a federal court considers whether the Attorney General acted improperly in moving state medical marijuana to Schedule III. An adverse ruling could unwind tax and banking benefits that have underpinned bullish cannabis investment theses, potentially erasing billions in market capitalization.
